Business Wire

73 Strings Announces Series A Funding Led by Blackstone and Fidelity International Strategic Ventures

12.7.2023 10:00:00 EEST | Business Wire | Press release

Share

73 Strings, the pioneering provider of valuation and portfolio monitoring solutions for the private capital industry, has completed its Series A funding round. The investment was led by Blackstone Innovations Investments, Blackstone's early-stage strategic investment arm, and Fidelity International Strategic Ventures (“FISV”), with participation from Broadhaven Ventures.

73 Strings is trusted by some of the world’s largest multi-strategy alternative investment firms across North America, Europe, and the Middle East with a client base that spans pension funds, sovereign wealth funds, limited partners (LPs), and general partners (GPs), including Eurazeo in France (€35B AUM), and Sofina in Belgium (€9B+ AUM). Today, the company’s platform is leveraged by clients with a combined AUM of over $2 trillion across Private Equity, Growth Equity, Venture Capital, and Private Credit strategies. 73 Strings will use the capital to continue to invest in building the product, engineering, and go-to-market teams.

“In a complex and volatile environment, it’s increasingly critical to alternative asset managers and their investors to deliver fast, frequent, and efficient valuations. This process is critical to keeping stakeholders well-informed. We’re enabling our customers to extract more information, intelligence, and value out of the portfolio monitoring and valuations process. We are thrilled to have the support of prestigious investors including Blackstone, FISV, and Broadhaven Ventures,” said Yann Magnan, co-founder and Chief Executive Officer at 73 Strings.

“With this funding, we are well-positioned to continue providing best-in-class technology solutions to the private capital industry. Our diverse skill sets and global footprint enable us to deliver products that shape the future of the industry,” said Abhishek Pandey, co-founder of 73 Strings.

The rapid growth and complexity of the alternatives industry increasingly requires scalable middle-office technology that can support the rise in the number of private investments within LP and GP portfolios. 73 Strings allows funds to move away from error-prone spreadsheets into a scalable software solution that streamlines the collection of portfolio company data and allows users to run automated valuations processes for private assets. The company’s integrated solution introduces efficiency, better risk management, and enhanced quality control to the portfolio monitoring and valuations processes.

“Blackstone knows firsthand that the growth of the alternatives industry and the innovation around new investment products requires scalable technology solutions. Valuations and portfolio monitoring are two of the most critical workflows in the private capital industry, and we believe there is a significant opportunity to introduce automation and efficiency into these areas. We’re thrilled to partner with Yann, Abhishek, and the 73 Strings team to further the platform’s growth and product development,” said Stevi Petrelli, Head of Blackstone Innovations Investments.

“Software has not kept pace with the dramatic increase in demand for private assets over the last decade. With 73 Strings’ unique combination of technology and private assets expertise, managers can scale efficiently and transform the drudgery of manual data entry into automated digital workflows. Digitizing private assets operations will unlock productivity, transparency, and ultimately enable greater liquidity. We are excited to partner with the team and support their mission to transform the alternative investment industry,” said Alokik Advani, Managing Partner, FISV.

About 73 Strings

73 Strings is a modern, integrated and holistic data collection, monitoring and valuation platform powering the private capital industry. The company has developed a next generation AI-powered platform to assist alternative investment funds in streamlining their middle-office processes. The platform enables funds to collect and seamlessly structure portfolio company data, monitor these companies and estimate their fair value at the click of a button. 73 Strings supports clients globally across multiple strategies including Private Equity, Growth Equity, Venture Capital and Private Credit.

Since inception, 73 Strings has added clients with combined assets under management of more than USD 2 trillion. The company is headquartered in Paris and has a global presence across New York, London, Paris, Toronto, and Bengaluru to support its growing customer base. The current leadership of 73 Strings has extensive professional expertise in private assets and the team is supported by a global network of highly seasoned advisors with a combined 300+ years of financial advisory and private markets experience.

For more information, please visit 73strings.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries
morgan@bevelpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye